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Cushing’s disease after pituitary surgeryDear Editor,
Cushing’s disease (CD), resulting from adrenocorticotropic
hormone (ACTH)-secreting pituitary adenoma, is rare, with
an annual incidence of 2e3 million people. Trans-
sphenoidal surgery (TSS) is the first-line treatment. How-
ever, the remission rate for initial TSS varies widely with a
substantial risk of persistent/recurrent disease. The diag-
nosis and management of persistent/recurrent CD still re-
mains a challenge for clinicians [1]. We present a case of CD
with rapid relapse within 2 months after effective TSS,
progressing to fatal recurrent intracranial hemorrhage.
A 43-year-old man, manifesting with typical Cushing’s
appearance, sought help for his rapid body weight loss of
13 kg within 2 months. His biochemistry revealed hyper-
glycemia (HbA1C, 13.4%; plasma glucose, 697 mg/dL), hy-
pokalemia (K, 2.6 mEq/L), metabolic alkalosis (pH 7.489;
HCO3 , 33.9 mM), elevated serum cortisol 33.97 (normal,
5e25 mg/dL) and plasma ACTH 346.06 (normal, 10e50 pg/
mL). Cushing’s disease was confirmed by a high dose
dexamethasone test (HDT) and pituitary magnetic reso-
nance imaging showing a pituitary macroadenoma (Fig. 1A
and B). Trans-sphenoidal adenomectomy was executed to
achieve declining plasma ACTH 42 pg/mL and serum
cortisol 20.73 mg/dL and marked clinical improvement
(HbA1c, 5.9%; K, 4.2 mEq/L) postoperatively. However, his
condition deteriorated again with raised plasma ACTH
(156 pg/mL) and serum cortisol 39.91 (mg/dL) 2 months
later. HDT and pituitary magnetic resonance imaging
confirmed recurrent Cushing’s disease. Re-operation,
radiotherapy, or bilateral adrenalectomy was strongly sug-
gested but the patient refused and disappeared thereafter.
When he came back, his plasma ACTH and serum cortisol
were extremely elevated to 433.2 pg/mL and 77.4 mg/dL,
respectively, combined with multiple spine fractures.Conflicts of interest: All authors declare no conflicts of interest.
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occurred (Fig. 1C and D), soon leading to his death.
There are different definitions for remission, persistent/
recurrent disease, and outcomes. Generally, postoperative
CD patients are divided into status of initial remission, late
remission, or persistent disease. The consensus statement
defines initial remission by postoperative morning cortisol
ranging from 2 mg/dL to 5 mg/dL within 2 weeks. Patients
have been further categorized into long-term outcomes of
cure, persistent, or recurrent disease. Disease cure is
defined as an ongoing need for cortisol replacement or
absence of hypercortisolism at last follow-up. Conversely,
persistent disease is biochemically defined by post-
operative serum cortisol >2 mg/dL or persistently elevated
24 hour urinary free cortisol (normal, 20e100 mg/day) [2].
Recurrent CD has been defined by elevated urinary free
cortisol or failure of HDT after initial remission. Both
persistent and recurrent CD after TSS are regarded as an
active CD state.
The achievement of an initial remission by TSS is
determined by several factors, such as the skills of the
neurosurgeon, surgical exploration (total hypophysectomy
or adenectomy), and tumor characteristics. The overall
initial remission rate is higher for microadenoma (78e96%)
than macroadenoma (53e76%). Predictors of disease
persistence/recurrence include tumors localized in the
cavernous sinus, dural invasion, extrasellar growth, or
higher proliferative rate with p53 immunopositivity. The
average time to recurrence is 2 years (range, from 4 months
to 16 years). Therefore, long-term follow-up of at least 10
years is obligatory [2].
There are several treatment choices patients of persis-
tent/recurrent CD, including repeat pituitary surgery,
radiotherapy, medication, and bilateral adrenalectomy. The
remission rate for repeat surgery is estimated at 50e70%.
Radiation therapy is valuable but limited by its delayed ef-
fect. Bilateral laparoscopic adrenalectomy is currentlyy Elsevier Taiwan LLC. All rights reserved.
Figure 1. (A) Sagittal and (B) coronal view of magnetic resonance imaging shows a pituitary macroadenoma
(1.4 cm  0.6 cm  0.9 cm) in the inferior part of pituitary gland. (C, D) axial view of brain computed tomography scan shows
intracranial hemorrhage over the right thalamus and internal capsule rupture into ventricle causing obstructive hydrocephalus.
58 Letter to the Editorindicated for very ill patients to achieve rapid control of
hypercortisolism. Medicines, including steroidogenesis in-
hibitors, centrally acting agents (cabergoline and pasireo-
tide), and glucocorticoid receptor antagonist, are usually
indicated as adjuvant therapy in preparation for surgery or
radiation to take effect. No current single option is sufficient
to achieve high success. Therefore, treatment of persistent/
recurrent CD always needs teamwork over time.
Excess morbidity and mortality in patients with CD,
including obesity, diabetes, hypertension, hyperlipidemia,
and osteoporosis is related to hypercortisolism [3]. The
cardiovascular risk is highest at the time of diagnosis to
remain elevated during follow-up. The overall standard
mortality ratio is 2e4 times higher than controls. The mean
age at death was 61.3 years, occurring 20 years earlier than
the general population, mostly caused by myocardial
infarction, stroke, uncontrolled diabetes, and sepsis [4,5].
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